Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Core Insights - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare skin diseases without FDA-approved treatments [1][3] - The company will present at the Stifel 2025 Healthcare Conference on November 12, 2025, at 4:00 p.m. ET [1] - Palvella's lead product candidate is QTORIN™ 3.9% rapamycin anhydrous gel, targeting microcystic lymphatic malformations, cutaneous venous malformations, and clinically significant angiokeratomas [3] - The second product candidate, QTORIN™ pitavastatin, is being developed for disseminated superficial actinic porokeratosis [3] Company Overview - Palvella Therapeutics was founded by veterans in rare disease drug development and is dedicated to creating novel therapies for patients with serious, rare skin diseases [3] - The company utilizes its patented QTORIN™ platform to develop a broad pipeline of product candidates [3] - Both QTORIN™ rapamycin and QTORIN™ pitavastatin are currently for investigational use only and have not received FDA approval [4]